• 1. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 2. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

Introduction to {3-Methylimidazo[1,5-a]pyridin-1-yl}methanol

{3-Methylimidazo[1,5-a]pyridin-1-yl}methanol is a synthetic organic compound that has garnered significant attention in the field of biomedical research. This molecule belongs to the class of imidazopyridines, which are known for their unique structural properties and diverse applications in drug discovery. The compound's IUPAC name, {3-Methylimidazo[1,5-a]pyridin-1-yl}methanol, reflects its intricate structure, combining elements of both imidazole and pyridine rings with a methyl group substitution at position 3 and a hydroxymethyl substituent at position 1.

The core structure of {3-Methylimidazo[1,5-a]pyridin-1-yl}methanol consists of an imidazo[1,5-a]pyridine framework. This bicyclic system features a five-membered imidazole ring fused to a six-membered pyridine ring in a specific orientation. The 3-methyl substitution adds a methyl group at position 3 of the imidazole ring, while the methanol substituent introduces a hydroxymethyl group (-CH2OH) at position 1. This combination creates a unique chemical entity with potential for various biological activities, including antimicrobial, anticancer, and neuroprotective properties.

Recent studies have highlighted the importance of imidazopyridine derivatives in drug development. These compounds are being explored for their ability to modulate a variety of enzymatic activities, such as matrix metalloproteinases (MMPs), which play a critical role in diseases like cancer and inflammatory disorders. The hydroxymethyl group in {3-Methylimidazo[1,5-a]pyridin-1-yl}methanol may enhance its bioavailability by increasing solubility, while the methyl substitution could influence metabolism and target binding affinity.

One of the most promising applications of {3-Methylimidazo[1,5-a]pyridin-1-yl}methanol lies in its potential as a anticancer agent. Preclinical studies have demonstrated that certain imidazopyridine derivatives can induce cell cycle arrest and apoptosis in various cancer cell lines. The compound's ability to inhibit angiogenesis, the process by which tumors develop new blood vessels, further underscores its therapeutic potential in oncology.

Another area of interest is the compound's neuroprotective effects. Research has shown that imidazopyridines can exhibit antioxidant and anti-inflammatory properties, which are critical for protecting neurons from damage caused by oxidative stress and inflammation. These findings suggest that {3-Methylimidazo[1,5-a]pyridin-1-yl}methanol could be a valuable candidate in the development of treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Furthermore, the compound has been investigated for its potential as an antimicrobial agent. With the rise of antibiotic resistance, there is a pressing need for new classes of compounds that can effectively combat bacterial infections. The unique structure of {3-Methylimidazo[1,5-a]pyridin-1-yl}methanol may provide a novel mechanism of action against resistant pathogens, making it a promising lead in the development of next-generation antimicrobials.

Recent advancements in crystallography and computational chemistry have provided deeper insights into the molecular interactions of {3-Methylimidazo[1,5-a]pyridin-1-yl}methanol with its biological targets. These studies have revealed how the compound's structure influences its binding affinity to specific receptors and enzymes, paving the way for rational drug design approaches. For instance, the hydroxymethyl group has been shown to play a crucial role in hydrogen bonding with key residues in enzyme active sites, enhancing the compound's inhibitory effects.

Additionally, advancements in delivery systems have addressed some of the challenges associated with the pharmacokinetics of {3-Methylimidazo[1,5-a]pyridin-1-yl}methanol. Research into nanoparticle delivery and pro-drug strategies has improved the compound's stability, bioavailability, and targeting efficiency, bringing it closer to clinical applications.

In conclusion, {3-Methylimidazo[1,5-a]pyridin-1-yl}methanol represents a compelling candidate for further exploration in biomedical research. Its unique structure, coupled with its demonstrated biological activities, positions it as a potential therapeutic agent in various disease areas, including cancer, neurodegenerative disorders, and infectious diseases. As our understanding of its mechanism of action continues to evolve, so too will the opportunities for its application in drug development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)